Status: Not yet recruiting
Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)
Randomized trial aimed to assess in adults with PsA the effect of oral CBP-0276 administrated at a dose of 200mg QD, or 800mg QD vs. Placebo for CBP-0276 for 24 weeks. Primary outcome is the change at least 20% on severity of symptoms eat week 24, using the American College Rheumatologic Score (ACR) and key secondary outcomes are the change on ACR20% at week 16 and ACR50/70% at week 24. Eligible patients will be randomly assigned (1:1:1) to receive oral CBP-0276 200mg QD, 800mg QD or placebo for CBP-0276 for 24 weeks
Participants needed: 240
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Clarent Biopharma, Inc.Updated: Jul 16, 2026Locations: 1
Eligibility criteria
Subject must voluntarily sign the informed consent form before any study-related... [+7]
History of Drug-induced psoriasis (including, but not limited to, psoriasis indu... [+21]